Skip to main content
. 2017 Mar 20;28(7):2188–2200. doi: 10.1681/ASN.2016070768

Table 4.

Comparison of costs and payments after 1 year, relative to rATG

Cost and Payment Outcomes Alemtuzumab Match (n=5330 Matched Pairs) Basiliximab Match (n=9378 Matched Pairs)
Alemtuzumab Matched rATG Paired Difference (95% CI) P Value Basiliximab Matched rATG Paired Difference (95% CI) P Value
1-yr total cost, $
 Mean 86,290 88,948 −2658 (−4648 to −668) <0.01 87,926 88,679 −753 (−2324 to 819) 0.35
 M-estimate 84,291 87,597 −3083 (−4858 to −1303) <0.001 85,990 87,134 −1058 (−2427 to 313) 0.13
1-yr total payment, $
 Mean 75,382 79,112 −3729 (−6614 to −844) 0.01 79,589 76,814 2775 (356 to 5195) 0.03
 M-estimate 73,500 76,346 −2847 (−5345 to −355) 0.03 76,102 74,183 1782 (−118 to 3685) 0.07

P values were calculated using the test of the weighted m-statistic for continuous m-estimates and the permutational t test for continuous means. M-estimate, maximum likelihood type estimate.